Retatrutide

Retatrutide (development code LY3437943, Eli Lilly) is a synthetic acylated peptide and investigational pharmaceutical agent belonging to the incretin-mimetic class. Unlike first-generation GLP-1 receptor agonists (semaglutide) or second-generation dual GLP-1/GIP agonists (tirzepatide), retatrutide is engineered as a tri-agonist: a single peptide molecule that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This places it at the leading edge of incretin pharmacology as of the current research landscape. For educational purposes only — the following information is a research summary, not medical advice.

The mechanism of action operates across three intersecting pathways. GLP-1R activation suppresses appetite, slows gastric emptying, and augments glucose-dependent insulin secretion — the same mechanism underpinning semaglutide. GIPR co-agonism appears to amplify GLP-1-mediated satiety signaling and may blunt nausea side effects, mirroring tirzepatide's profile. The addition of glucagon receptor agonism is the key differentiator: GCGR activation increases hepatic glucose output and, importantly, stimulates energy expenditure and fatty acid oxidation in a fasted-state-mimicking manner. Preclinical research in rodent models suggested this glucagon component drives substantially greater fat mass reduction than GLP-1 or GIP agonism alone, while the GLP-1 co-agonism is theorized to offset the hyperglycemic risk that would otherwise accompany isolated glucagon receptor stimulation.

The most significant published human evidence comes from a Phase 2 randomized controlled trial (Jastreboff et al., NEJM, 2023) enrolling 338 adults with obesity (BMI ≥ 27 kg/m²) without type 2 diabetes. Over 48 weeks, the highest-dose cohort (12 mg weekly subcutaneous injection) demonstrated a mean weight reduction of approximately 24.2% from baseline. Lower dose cohorts (4 mg and 8 mg) reported mean reductions of roughly 8.7% and 17.5%, respectively. Participants in type 2 diabetes cohorts within the same trial series showed meaningful HbA1c reductions alongside weight loss, though the non-diabetic obesity trial produced the most cited efficacy figures. These are human RCT data, which distinguishes retatrutide from most research-chemical peptides covered on this platform — however, the compound remains unapproved and is not commercially available outside of clinical trial contexts. Phase 3 trials (TRIUMPH program) were ongoing as of the available research horizon; readers should check ClinicalTrials.gov (NCT05929066 and related registries) for current status.

Dosing in the Phase 2 research context involved subcutaneous weekly injections with an escalation schedule starting at 2 mg and titrating to target doses of 4 mg, 8 mg, or 12 mg over several weeks. This escalation protocol is standard for incretin-class agents and is designed to mitigate gastrointestinal side effects. These dose ranges are reported strictly in published research contexts and constitute no recommendation for self-administration. Retatrutide is not legally obtainable as a research chemical with verified identity — any compound sold under this name outside of a licensed clinical trial setting cannot be confirmed as authentic retatrutide, carries unknown purity and safety profiles, and should be approached with extreme caution.

From a legal and sourcing standpoint, retatrutide occupies an unusual position. It is not FDA-, EMA-, MHRA-, or TGA-approved, meaning there is no legal prescription pathway for it in any major jurisdiction as of the available research date. Unlike semaglutide or tirzepatide — which can be accessed via licensed telehealth providers and compounding pharmacies under specific regulatory frameworks — retatrutide has no such legitimate channel. Any vendor offering retatrutide as a research chemical cannot be supplying verified pharmaceutical-grade material; the compound is proprietary to Eli Lilly and not available through standard peptide synthesis supply chains with confirmed structural identity. Researchers and clinicians interested in access should monitor Eli Lilly's clinical trial enrollment pathways. This profile is published for educational and research-literacy purposes only.